CellWell record HH-379019
First-in-human assessment of actinium-225-prostate-specific membrane antigen ( 225 Ac-PSMA)-Trillium (BAY 3563254) in mCRPC: Dose-escalation results of the phase 1 PAnTHa study.
Fred Saad; S. Hotte; A. Jayaram; C. Artigas; R. Saleh; Corinne Maurice-Dror; S. Van Bruwaene; C. Boixareu; N. Tunariu; Z. Hamilou; D. Juneau; C. Glaus
Journal of Clinical Oncology ยท 2026
In plain language
225Ac-PSMA-Trillium alpha-emitter achieved 46% response rate and 83% PSA50 response at the recommended dose in metastatic castration-resistant prostate cancer.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-379019
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.